ABSTRACT
Crowd monitoring was an essential measure to deal with over-tourism problems in urban destinations in the pre-COVID era. It will play a crucial role in the pandemic scenario when restarting tourism and making destinations safer. Notably, a Destination Management Organisation (DMO) of a smart destination needs to deploy a technological layer for crowd monitoring that allows data gathering in order to count visitors and distinguish them from residents. The correct identification of visitors versus residents by a DMO, while privacy rights (e.g., Regulation EU 2016/679, also known as GDPR) are ensured, is an ongoing problem that has not been fully solved. In this paper, we describe a novel approach to gathering crowd data by processing (i) massive scanning of WiFi access points of the smart destination to find SSIDs (Service Set Identifier), as well as (ii) the exposed Preferred Network List (PNL) containing the SSIDs of WiFi access points to which WiFi-enabled mobile devices are likely to connect. These data enable us to provide the number of visitors and residents of a crowd at a given point of interest of a tourism destination. A pilot study has been conducted in the city of Alcoi (Spain), comparing data from our approach with data provided by manually filled surveys from the Alcoi Tourist Info office, with an average accuracy of 83%, thus showing the feasibility of our policy to enrich the information system of a smart destination.
ABSTRACT
OBJECTIVES: We sought to investigate stent healing and neointimal hyperplasia with ihtDEStiny drug-eluting stent (DES) by optical coherence tomography (OCT) examination conducted 9 months after implantation. BACKGROUND: The currently used DES present certain features that have been linked separately to their better performance in terms of efficacy and safety. METHODS: First-in-man, prospective and multicenter study including patients treated with ihtDEStiny stent undergoing OCT examination at 9 months follow up. The ihtDEStiny stent is a sirolimus eluting stent with an oval shape ultrathin struts (68 µm) and an abluminal coating of a fluoropolymer containing the antiplatelet agent triflusal. Primary endpoint was the percentage of obstruction of the in-stent volume by the neointima. RESULTS: In 58 patients (63 lesions) in-stent late lumen loss was 0.11 ± 0.23 mm (95% CI 0.05-0.16) with only in 6% of stents being > 0.5 mm and in-segment binary stenosis was 1.6%. In OCT mean neointima volume obstruction was 10.5 ± 6.9% with a mean neointima thickness of 110.9 ± 89.8 µm. The proportion of uncovered struts was 2.5%, malapposed struts 1.1% and malapposed/uncovered struts 0.7% and no subclinical thrombi detected. Mean incomplete stent apposition area was 0.1 ± 0.1 mm2. At 12 months target lesion revascularization rate was 3% and no stent thrombosis was reported. CONCLUSIONS: In this study the ihtDEStiny stent has shown a very low degree of neointimal proliferation associated with a low rate of uncovered/malapposed struts and total absence of subclinical thrombi at 9 months follow up.